Clinical trials: Pulmonary Injury After Intracerebral Hemorrhage
Pulmonary Injury After Intracerebral Hemorrhage
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
Some patients with intracerebral hemorrhage will develop severe lung injury such as respiratory distress syndrome. Baricitinib has been approved by the FDA for severe pneumonia caused by the coronavirus, and has been used in the…
- Trial name
- BRIGHT (NCT06548802)
- Testing
- Baricitinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Medical University General Hospital